PPAR Research · 2012 · 44 citations · 42 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCell Cycle PharmacologyPharmacodynamics Of Anticancer AgentsPharmacodynamics Of Anticancer DrugsProstate CancerSignal Transduction In CancerAntiproliferative AgentsAntiproliferative Drug ActionCancer Signaling PathwaysErk SignalingMapk SignalingMek InhibitorsMek SignalingWestern Blot Analysis
Thiazolidinediones (TZDs) dramatically reduce the growth of human prostate cancer cells in vitro and in vivo. To determine whether the antitumor effects of TZDs were due in part to changes in the MEK/Erk signaling pathway, we examined the regulation of Erk phosphorylation by the TZD troglitazone within the PC-3 and C4-2 human prostate cancer cell lines. Western blot analysis revealed troglitazone-induced phosphorylation of Erk in both PC-3 and C4-2 cells. Troglitazone-induced increases in Erk phosphorylation were suppressed by the MEK inhibitor U0126 but not by the PPARγ antagonist GW9662. Pretreatment with U0126 did not alter the ability of troglitazone to regulate expression of two proteins that control cell cycle, p21, and c-Myc. Troglitazone was also still effective at reducing PC-3 proliferation in the presence of U0126. Therefore, our data suggest that troglitazone-induced Erk phosphorylation does not significantly contribute to the antiproliferative effect of troglitazone.
42
Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ
Erding Hu, Jae Bum Kim, Pasha Sarraf et al. · Science · 1996 · 1K citations
Elena Elstner, Carsten Müller‐Tidow, Kozo Koshizuka et al. · Proceedings of the National Academy of Sciences · 1998 · 796 citations · Full text